PGx testing, short for pharmacogenomic testing, is a type of genetic test that reveals how your body is likely to process specific medications. It uses a small blood draw or saliva sample to analyze genes involved in drug metabolism, helping your doctor choose the right medication at the right dose. The core idea is simple: your DNA can explain why a drug that works perfectly for one person causes side effects or does nothing for someone else.
How Genetics Affect Drug Response
Most medications are broken down by enzymes in your liver before they’re absorbed, used, or cleared from your body. The most important family of these enzymes is called cytochrome P450, or CYP for short. Dozens of genetic variations exist across CYP enzymes, and the specific combination you inherited from your parents determines how quickly or slowly you metabolize certain drugs.
Beyond liver enzymes, your genes also influence drug transporters, the proteins that move medications across cell membranes throughout your body. Variations in transporter genes can change how much of a drug actually reaches the tissue where it’s supposed to work. Together, these enzyme and transporter differences explain a large share of why two people taking the same pill can have vastly different experiences.
Metabolizer Types and What They Mean
PGx results categorize you into one of several metabolizer types for each gene tested. According to the FDA’s classifications:
- Normal metabolizer: You don’t carry genetic variants expected to change how you process the drug. Standard dosing typically applies.
- Ultrarapid metabolizer: You carry two or more copies of a variant that speeds up enzyme activity. You may break down a drug so fast it never reaches effective levels, or in the case of prodrugs (medications that become active only after metabolism), you may convert too much too quickly and experience toxicity.
- Intermediate metabolizer: You carry one or two copies of a variant that partially reduces enzyme function. You may need a lower dose or closer monitoring.
- Poor metabolizer: You carry two copies of a variant that leaves you with little to no enzyme activity. Drugs may build up to dangerous levels, or prodrugs may never activate at all.
These categories matter in concrete ways. Codeine, for example, relies on the CYP2D6 enzyme to convert it into morphine. An ultrarapid metabolizer can produce dangerously high morphine levels from a standard codeine dose, while a poor metabolizer gets almost no pain relief because the conversion barely happens.
Which Drugs and Conditions It Covers
PGx testing is most established in psychiatry, cardiology, pain management, and oncology. The CYP2D6 enzyme alone is involved in processing roughly one-quarter of all medications. CYP2C19 and CYP2C9 cover additional large groups. Some of the most commonly flagged drug-gene interactions include:
- Antidepressants: SSRIs like citalopram and escitalopram are primarily metabolized by CYP2C19. Tricyclics like amitriptyline depend on both CYP2C19 and CYP2D6.
- Blood thinners: Warfarin dosing is influenced by CYP2C9 and another gene called VKORC1. Getting the dose wrong can cause dangerous bleeding or ineffective clot prevention.
- Pain medications: Codeine and oxycodone both rely on CYP2D6 to produce their active pain-relieving forms.
- Acid reflux drugs: Proton pump inhibitors like omeprazole and lansoprazole are cleared by CYP2C19, so poor metabolizers may experience stronger effects or more side effects at standard doses.
- Cancer drugs: Fluoropyrimidine-based chemotherapies depend on an enzyme called DPD. Patients with reduced DPD activity face a significantly higher risk of severe, sometimes life-threatening toxicity from standard doses.
- Antipsychotics: Risperidone is metabolized primarily by CYP2D6, meaning poor metabolizers can accumulate the drug and experience amplified side effects.
How the Test Works
The test itself is straightforward. Your provider collects either a blood sample or a cheek swab. The sample goes to a lab that sequences the relevant portions of your DNA, and a report comes back categorizing your metabolizer status for each gene analyzed. Most panels test multiple genes at once rather than one at a time. Results are typically permanent since your DNA doesn’t change, so you generally only need the test once per gene.
Evidence That It Reduces Side Effects
A large clinical trial involving nearly 7,000 patients across primary care, oncology, and general medicine compared genotype-guided prescribing to standard care. Patients whose doctors used PGx results had a 33% lower risk of adverse drug reactions (21.5% experienced a reaction compared to 28.6% in the standard care group). Perhaps most striking, 93.5% of participants carried at least one actionable gene variant, meaning the vast majority of people have genetic differences relevant to at least one common medication.
What Medicare and Insurance Cover
Medicare covers PGx testing under specific conditions, but not as a blanket screening tool. Coverage requires that your doctor has already narrowed down treatment options based on your diagnosis, medical history, other medications, and clinical judgment. The test must be tied to a specific medication that has a known, clinically actionable gene-drug interaction recognized by the FDA or the Clinical Pharmacogenetics Implementation Consortium (CPIC).
In practical terms, this means your doctor can’t order PGx testing simply because you have depression or heart disease. They need to be actively considering, or already prescribing, a specific drug known to have a meaningful genetic interaction. The ordering provider must also be licensed to both diagnose the condition and prescribe the medication in question. Private insurance policies vary widely, and some direct-to-consumer tests are available out of pocket, with costs ranging from under $100 to several hundred dollars depending on how many genes are included.
What PGx Testing Cannot Do
Genetics is one piece of a much larger puzzle. Your drug response is also shaped by age, weight, kidney and liver function, diet, other medications you’re taking, and whether you actually take the drug consistently. Two drugs can compete for the same enzyme, effectively turning a normal metabolizer into a poor one regardless of what their genes say. PGx testing cannot predict every possible side effect, diagnose a disease, or guarantee that a medication will work. It narrows the odds of a bad outcome, but it doesn’t eliminate uncertainty.
Results also require interpretation by a provider who understands both the clinical context and the pharmacogenomic data. A test result showing you’re a poor metabolizer for CYP2D6 only matters if the drug you’re taking actually uses that pathway. Panel results can look alarming in isolation but may be completely irrelevant to your current prescriptions.